Monoclonal Antibodies against Beta-2-Glycoprotein I: Use as Reference Material for Lupus Anticoagulant Tests

Summary

The laboratory diagnosis of lupus anticoagulants (LA) remains difficult despite internationally accepted guidelines for its detection. Several interlaboratory surveys have shown poor agreement between laboratories. Further standardization of LA testing will to a large extent depend on better insights on the mechanisms by which LA affect phospholipid-dependent coagulation assays as well as on the availability of well characterized and internationally accepted reference materials and control specimens. We recently raised a series of murine monoclonal antibodies against human β₂GPI (anti-β₂GPI moabs), a phospholipid-binding protein directly involved in the interaction between certain lupus anticoagulants and phospholipids. In this study we report on the use of LA positive anti-β₂GPI moabs as easy to handle reference and control material. The relative LA responsiveness of various phospholipid-dependent clotting assays was determined on plasmas spiked with such moabs and compared well with that determined on LA positive plasma samples. Plasmas spiked with LA positive anti-β₂GPI moabs were also used as control specimens to study the interlaboratory precision of LA testing. With these control specimens, low interassay coefficients of variation were obtained. Our results indicate that LA positive anti-β₂GPI moabs have potential for the production of control specimens that could be made available to routine hemostasis laboratories to assess intra-laboratory precision of LA testing and to manufacturers to control batch-to-batch variability of their reagents.

• References

• 1 McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
• 2 Vermylen J, Blockmans D, Spitz B, Arnout J, Grillet B. Thrombosis as an immune phenomenon. Baillière’s Clinical Immunology and Allergy 1987; 1: 619-41.
• 3 Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-98.
• 4 Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991; 65: 320-2.
• 5 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
• 6 Roussi J, Roisin JP, Goguel A. Lupus anticoagulants. First French Interlaboratory Etalanorme Survey. Am J Clin Pathol 1996; 105: 788-93.
• 7 Jennings I, Kitchen S, Woods TAL, Preston FE, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK national external quality assessment scheme (NEQAS) for blood coagulation. Thromb Haemost 1997; 77: 934-7.
• 8 Brandt JT, Barna K, Triplett DA. Laboratory identification of lupus anticoagulants: results of the second international workshop for identification of lupus anticoagulants. Thromb Haemost 1995; 74: 1597-603.
• 9 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
• 10 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
• 11 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
• 12 Galli M, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anticoagulant activity of β₂-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
• 13 Vermylen J, Arnout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes?. J Lab Clin Med 1992; 120: 10-2.
• 14 Arnout J, Wittevrongel C, Vanrusselt M, Hoylaerts M, Vermylen J. Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody-beta-2-glycoprotein I complexes on phospholipid surfaces. Thromb Haemost 1998; 79: 79-86.
• 15 Willems GM, Janssen MP, Pelsers MMAL, Confurius P, Galli M, Zwaal RFA, Bevers EM. Role of divalency in the high affinity binding of anticardiolipin antibody-β₂-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
• 16 Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, Ichikawa K, Koike T, Suzuki K. Anti-β₂-Glycoprotein I (β₂GP I) monoclonal antibodies with lupus anticoagulant-like activity enhance the β₂GP I binding to phospholipids. J Clin Invest 1997; 99: 2260-8.
• 17 Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimisation of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-9.
• 18 Exner T. Comparison of two simple tests for the lupus anticoagulant. Am J Clin Pathol 1985; 83: 215-8.
• 19 Lesperance B, David M, Rauch J, Infante-Rivard C, Rivard GE. Relative sensitivity of different tests in the detection of low titer lupus anticoagulants. Thromb Haemost 1988; 60: 217-9.
• 20 Lo SCL, Oldmeadow MJ, Howard MA, Firkin BG. Comparison of laboratory tests used for identification of the lupus anticoagulant. Am J Hematol 1989; 30: 213-20.
• 21 Liu HW, Wong KL, Lin CK, Wong WS, Tse PWT, Chan GTC. The reappraisal of dilute tissue thromboplastin inhibition test in the diagnosis of lupus anticoagulant. Br J Haematol 1989; 72: 229-34.
• 22 Forastiero RR, Falcon CR, Carreras LO. Comparison of various screening and confirmatory tests for the detection of the lupus anticoagulant. Haemostasis 1990; 20: 208-14.
• 23 Exner T, Triplett DA, Taberner DA, Howard MA, Harris EN. Comparison of test methods for the lupus anticoagulant: international survey on lupus anticoagulants-I (ISLA-I). Thromb Haemost 1990; 64: 478-84.
• 24 Forastiero RR, Cerrato GS, Carreras LO. Evaluation of recently described tests for detection of the lupus anticoagulant. Thromb Haemost 1994; 75: 728-33.
• 25 Martin BA, Branch DW, Rodgers GM. Sensitivity of the activated partial thromboplastin time, the dilute Russell’s viper venom time, and the kaolin clotting time for the activation of the lupus anticoagulant: a direct comparison using plasma dilutions. Blood Coagul Fibrinolysis 1996; 7: 31-8.
• 26 Brandt JT, Triplett DA, Musgrave K, Orr C. The sensitivity of different coagulation reagents to the presence of lupus anticoagulant. Arch Pathol Lab Med 1987; 111: 120-4.
• 27 Denis-Magdelaine A, Flahault A, Verdy E. Sensitivity of sixteen aPTT reagents for the presence of lupus anticoagulants. Haemostasis 1995; 25: 98-105.
• 28 Brancaccio V, Ames PRJ, Glynn J, Iannaccone L, Mackie IJ. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive aPTT reagent. Blood Coagul Fibrinolysis 1997; 8: 155-60.
• 29 Horbach DA, van Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.